Please use this identifier to cite or link to this item:
|Title:||Acute liver injury leading to death in the setting of brentuximab vedotin monotherapy|
Acute Liver Injury
Single-Agent Brentuximab Vedotin
Hepatotoxicity of Brentuximab Vedotin
|Publisher:||Taylor & Francis|
|Citation:||Leuk Lymphoma. 2019 Mar 1:1-4. doi: 10.1080/10428194.2019.1579321. [Epub ahead of print]|
|Abstract:||A 67-year-old man with an 11-year history of composite lymphoma was admitted with fevers in the context of neutropenia and acute liver injury, 4 months after the commencement of single-agent brentuximab vedotin. Fevers resolved with intravenous antibiotics, however, his liver function tests remained abnormal and he continued to be deeply jaundiced over the course of his 3-week illness. A liver screen failed to indicate a cause for his liver function test abnormalities and two separate liver biopsies were suggestive of drug-induced liver injury. There was no evidence on biopsy of lymphoma. After consultation with two hepatologists, trials of steroids and ursodeoxycholic acid were unsuccessful. Twenty-five days into admission, he became septic with a normal peripheral blood count and deteriorated rapidly. After discussion with the family, he was deemed not to be for further escalation of care, and he died within several hours. This report summarizes the evidence in relation to hepatotoxicity of brentuximab vedotin.|
|Journal Title:||Leukemia & Lymphoma|
|Affiliated Organisations:||Oncology Department, Eastern Health, Box Hill Hospital, Melbourne, Australia|
Gastroenterology Department, Alfred Health, Monash University, Prahran, Melbourne, Australia
|Appears in Collections:||General Surgery and Gastroenterology|
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.